Login to Your Account

GenKyoTex Moves NOX Inhibitor To Phase I; Starts Partner Hunt

By Nuala Moran
BioWorld International Correspondent

Wednesday, November 2, 2011

LONDON – GenKyoTex has begun initial prospecting for commercialization partners as its first-in-class dual NOX inhibitor, GKT137831, enters Phase I trials, and academic collaborators deliver further evidence of the drug's therapeutic effect in models of diabetic nephropathy.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription